Clinical Trial - NCT03584009

A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

Active, not recruiting

Sponsor: Hoffmann-La Roche


Information provided by (Responsible party): Sponsor Identifier: NCT03584009

Protocol Info

Short Description: Fulvestrant +/- Venetoclax in Breast Cancer
Long Description: A Phase II, Multicenter, Randomized Study to Compare the Efficacy of Venetoclax Plus Fulvestrant in Women with Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Experienced Disease Recurrence or Progression During or After CDK4/6 Inhibitor Therapy
MGH Status: Closed
Sponsor: Hoffman-LaRoche
Disease Program: Breast

Next Steps

If you are interested in this protocol or in other treatment options at Massachusetts General Hospital, please Request a Consultation.


This is a Phase II, multicenter, open-label, randomized study to compare the efficacy of venetoclax in combination with fulvestrant compared with fulvestrant alone in women with ER+, HER2-negative, inoperable, locally advanced or MBC who experienced disease recurrence or progression during or after treatment with CDK4/6i therapy for at least 8 weeks.
Condition Title Intervention Phase
Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Adva Venetoclax Fulvestrant Phase 2
Study Type Interventional
Official Title A Phase II, Multicenter, Randomized Study To Compare The Efficacy Of Venetoclax Plus Fulvestrant Versus Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

Primary Outcome Measures

Clinical benefit defined as Complete Response (CR), Partial Response (PR) or Stable Disease (SD) lasting >= 24 weeks [Time Frame: Randomization in patients with measurable disease at baseline through the end of study (2 years after the last patient is enrolled)] [Designated as safety issue: ]

Secondary Outcome Measures

Progression Free Survival (PFS) [Time Frame: Randomization to the first occurrence of disease progression as determined by the investigator according to (RECIST v1.1 ) or death from any cause, until the end of study (2 years after the last patient is enrolled)] [Designated as safety issue: ]

Objective Response (OR) [Time Frame: Objective Response defined as Complete Response (CR) or Partial response (PR), as determined by the investigator according to RECIST v1.1 from Randomization of patient until end of the study (2 years after the last patient enrolled)] [Designated as safety issue: ]

Duration of Response (DOR) [Time Frame: Time from first occurrence of a documented Objective response to the time of the first documented disease progression or death from any cause, whichever occurs first, until end of the study (2 years after the last patient enrolled)] [Designated as safety issue: ]

Overall Survival (OS) [Time Frame: Randomization to death from any cause, through the end of study (2 years after the last patient enrolled)] [Designated as safety issue: ]

Percentage of participants with adverse events [Time Frame: Baseline to end of study (2 years after the last patient enrolled)] [Designated as safety issue: ]

Plasma concentration of Venetoxclax and fulvestrant [Time Frame: At pre-defined intervals from Cycle 1, Day 1, through end of treatment (2 years after the last patient enrolled).] [Designated as safety issue: ]

Mean changes from baseline scores in functional disease/treatment-related symptoms and global health status health-related quality of life (GHS/HRQoL) by cycle [Time Frame: Baseline, cycle 1 day 1, and all subsequent cycles through at the end of treatment/discontinuation visit (2 years after the last patient enrolled)] [Designated as safety issue: ]

Change in baseline pain score as assessed by the pain scale of EORTC QLQ-C30 [Time Frame: Baseline through end of study (2 years after the last patient enrolled)] [Designated as safety issue: ]

Baseline BCL-2 protein levels as measured by International Council for Harmonisation (IHC) correlating with clinical response measures [Time Frame: Baseline through the end of study (2 years after the last patient enrolled)] [Designated as safety issue: ]

Estimated Enrollment: 103
Study Start Date: September 2018
Estimated Study Completion Date: February 2022
Estimated Primary Completion Date: August 2020
Arms Assigned Interventions

Experimental:Venetoclax + Fulvestrant

Participants in the venetoclax arm will receive venetoclax, taken orally and fulvestrant administered as IM injections until disease progression, unacceptable toxicity, withdrawal of consent, death, or predefined end of the study (2 years after the last patient is enrolled) which ever occur first.
Venetoclax will be administered orally, 800-mg tablet beginning on Cycle 1 Day 1

Active Comparator:Fulvestrant

Participants will receive fulvestrant administered as IM (intramuscular) injections. No crossover to the venetoclax arm is permitted. Study treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, death, or predefined end of the study (2 years after the last patient is enrolled) which ever occur first.
Fulvestrant will be administered orally, 500 mg administered as two 250-mg intramuscular (IM) injections on Cycle 1 Days 1 and 15 and on Day 1 of each subsequent 28-day cycle


Ages Eligible for Study: N/A-N/A

Genders Eligible for Study: Female

Accepts Healthly Volunteers: No

Inclusion Criteria:

  • Histological or cytological confirmation of estrogen receptor-positive (ER+) invasive carcinoma of the breast. ER+, HER2- negative invasive carcinoma of the breast with evaluable sample for BCL-2 IHC value at the time of screening. Participants who were originally diagnosed with HER2-positive breast cancer that converted to HER2-negative MBC are not eligible.
  • Evidence of metastatic or locally advanced disease not amenable to surgical or local therapy with curative intent
  • Be postmenopausal or pre- or perimenopausal women amenable to being treated with the luteinizing hormone-releasing hormone (LHRH) agonist goserelin
  • Participants must not have received more than two prior lines of hormonal therapy in the locally advanced or metastatic setting. In addition, at least one line of treatment must be a CDK4/6i AND participants must have experienced disease recurrence or progression during or after CDK4/6i therapy, which must have been administered for a minimum of 8 weeks prior to progression.
  • Participants for whom endocrine therapy (e.g., fulvestrant) is recommended and treatment with cytotoxic chemotherapy is not indicated at the time of entry into the study, as per national or local treatment guidelines
  • Women of childbearing potential (i.e., not postmenopausal for at least 12 months or surgically sterile) must have a negative serum pregnancy test result at screening, within 14 days prior to the first study drug administration
  • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use non-hormonal contraceptive methods with a failure rate of <1% per year during the treatment period and for 28 days after the last dose of study drug. Women must refrain from donating eggs during this same period.
  • Willing to provide tumor biopsy sample
  • Have at least one measurable lesion via RECIST v1.1
  • Have an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-1
  • Have adequate organ and marrow function
  • Have a life expectancy > 3 months
  • To full fill the coagulation requirements for patient with or without therapeutic anticoagulation

Exclusion criteria:

  • Prior treatment with fulvestrant or other selective estrogen receptor degraders (SERDs), venetoclax, or any agent whose mechanism of action is to inhibit BCL-2
  • Pregnant, lactating, or intending to become pregnant during the study
  • Known untreated or active Central Nervous System (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control
  • Prior chemotherapy in the locally advanced or metastatic setting regardless of the duration of the treatment.
  • Any anti-cancer therapy received within 21 days of the first dose of study drug, including chemotherapy, radiotherapy, hormonal therapy, immunotherapy, antineoplastic vaccines, or other investigational therapy. (Radiotherapy with palliative intent to non-target sites is allowed).
  • Concurrent radiotherapy to any site or prior radiotherapy within 21 days of Cycle 1 Day 1 or previous radiotherapy to the target lesion sites (the sites that are to be followed for determination of a response) or prior radiotherapy to > 25% of bone marrow
  • Current severe, uncontrolled, systemic disease (e.g., clinically significant cardiovascular, pulmonary, metabolic or infectious disease
  • Any major surgery within 28 days of the first dose of study drug or anticipation of the need for major surgery during the course of study treatment
  • Consumption of one or more of the following within 3 days prior to the first dose of study drug: Grapefruit or grapefruit products; Seville oranges including marmalade containing Seville oranges; Star fruit (carambola)
  • Administration within 7 days prior first dose of study treatment of Steroid therapy for anti-neoplastic intent, Strong or moderate CYP3A inhibitors or Strong or moderate CYP3A inducers
  • Need for current chronic corticosteroid therapy (> 10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids)
  • Known infection with (human immunodeficiency virus) HIV or human T-cell leukemia virus 1
  • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to Cycle 1 Day).
  • Participants who are positive for HCV antibody must be negative for HCV by PCR to be eligible for study participation. Participants with a past or resolved hepatitis B virus (HBV) infection (defined as having a positive total HBcAb and negative hepatitis B surface antigen [HbsAg]) may be included if HBV DNA is undetectable. These participants must be willing to undergo monthly DNA testing
  • Positive test results for hepatitis B core antibody (HBcAb) or hepatitis C virus (HCV) antibody at screening
  • Active HCV infection, defined as having a positive HCV antibody test at screening
  • History of other malignancies within the past 5 years except for treated skin basal cell carcinoma, squamous cell carcinoma, non-malignant melanoma <= 1.0 mm without ulceration, localized thyroid cancer, or cervical carcinoma in-situ
  • Administration of a live, attenuated vaccine within 4 weeks prior to initiation of study treatment or anticipation of need for such a vaccine during the study
  • Cardiopulmonary dysfunction
  • Other medical or psychiatric conditions that, in the opinion of the investigatory, may interfere with the participant's participation in the study
  • Inability or unwillingness to swallow pills or receive intramuscular (IM) injections
  • History of malabsorption syndrome or other condition that would interfere with enteral absorption
  • History of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis) or active bowel inflammation (e.g., diverticulitis)
  • Concurrent hormone replacement therapy
  • Inability to comply with study and follow-up procedures
  • History or active cardiopulmonary dysfunction
  • Known hypersensitivity to any of the study medications (fulvestrant, venetoclax) or to any of the excipients.

Contacts and Locations

Please refer to this study by its identifier: NCT03584009


  • United States, Arizona
    • Mayo Clinic Hospital Phoenix, Arizona, United States, 85054
  • United States, Arkansas
    • Highlands Oncology Group Fayetteville, Arkansas, United States, 72703
  • United States, California
    • UC San Deigo Moores Cancer Center La Jolla, California, United States, 92037
    • Comprehensive Cancer Center at Desert Regional Medical Center Palm Springs, California, United States, 92262
    • St. Joseph Health Medical Group - Annadel Medical Group Santa Rosa, California, United States, 95403-1757
  • United States, Florida
    • Sylvester Comprehensive Cancer Center - Deerfield Beach; Sylvester Cancer Center Deerfield Beach, Florida, United States, 33442
  • United States, Georgia
    • Northwest Georgia Oncology Centers PC - Marietta Marietta, Georgia, United States, 30060
  • United States, Hawaii
    • Kaiser Permanente - Moanalua Medical Center Honolulu, Hawaii, United States, 96819-1469
  • United States, Kentucky
    • Ashland-Bellefonte Cancer Center Ashland, Kentucky, United States, 41101-7016
  • United States, Maryland
    • University of Maryland Medical Center Baltimore, Maryland, United States, 21201
  • United States, Massachusetts
    • Massachusetts General Hospital. Boston, Massachusetts, United States, 02114
    • Mass General/North Shore Cancer Danvers, Massachusetts, United States, 01923
  • United States, Minnesota
    • Abbott Northwestern Hospital Minneapolis, Minnesota, United States, 55407
  • United States, Nebraska
    • Nebraska Hematology Onco, PC Lincoln, Nebraska, United States, 68506
  • United States, New Mexico
    • University of New Mexico Cancer Center Albuquerque, New Mexico, United States, 87131
  • United States, Ohio
    • Cleveland Clinic Cleveland, Ohio, United States, 44195
  • United States, South Dakota
    • Sanford Health System Sioux Falls, South Dakota, United States, 57105
  • United States, Texas
    • The University of Texas Southwestern Medical Center at Dallas Dallas, Texas, United States, 75390
    • The Center for Cancer and Blood Disorders - Fort Worth Fort Worth, Texas, United States, 76104
    • Millennium Oncology Houston, Texas, United States, 77090
  • United States, Washington
    • Providence Regional Cancer Partnership Everett, Washington, United States, 98201
  • Australia, New South Wales
    • Mater Hospital; Patricia Ritchie Centre for Cancer Care and Research North Sydney, New South Wales, Australia, 2059
  • Australia, Queensland
    • Mater Misericordiae Limited South Brisbane, Queensland, Australia, 4101
  • Australia, Victoria
    • Peter MacCallum Cancer Center Melbourne, Victoria, Australia, 3000
  • Canada, Ontario
    • Southlake Regional Health Center Newmarket, Ontario, Canada, L3Y 2R2
    • The Ottawa Hospital Ottawa, Ontario, Canada, K1H 8L6
    • Sunnybrook Health Sciences Centre Toronto, Ontario, Canada, M4N 3M5
  • Canada, Quebec
    • CHUS - Hôpital Fleurimont Sherbrooke, Quebec, Canada, J1H 5N4
  • Germany,
    • Hämato-Onkologische Schwerpunktpraxis am Klinikum Aschaffenburg Aschaffenburg, , Germany, 63739
    • Universitätsklinikum Erlangen; Frauenklinik Erlangen, , Germany, 91054
    • Klinikum Frankfurt Höchst GmbH Frankfurt, , Germany, 65929
    • Facharztzentrum Eppendorf, Studien GbR Hamburg, , Germany, 20249
    • Rotkreuzklinikum München; Frauenklinik Muenchen, , Germany, 80637
    • Gemeinschaftspraxis für Hämatologie und Onkologie GbR; Dechow & Decker & Nonnenbroich Ravensburg, , Germany, 88212
    • Klinikum Südstadt Rostock Rostock, , Germany, 18059
  • United Kingdom,
    • Royal United Hospital Bath NHS Trust Bath, , United Kingdom, BA1 3NG
    • Royal Sussex County Hospital Brighton, , United Kingdom, BN2 5BE
    • Barts Health NHS Trust - St Bartholomew's Hospital London, , United Kingdom, EC1A 7BE
    • The Christie NHS Foundation Trust Manchester, , United Kingdom, M20 4BX
    • Nottingham University Hospitals NHS Trust - City Hospital Nottingham, , United Kingdom, NG5 1PB

Sponsors and Collaborators

Hoffmann-La Roche

More Information

No publications provided

Responsible Party: Sponsor Identifier: NCT03584009
Other Study ID Numbers: 2017-005118-74
Study First Received:
Last Updated:
Health Authority:

Additional relevant MeSH terms:

Breast Neoplasms




Next Steps

If you are interested in this protocol or in other treatment options at Massachusetts General Hospital, please Request a Consultation. processed this data on September 03, 2020